CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Immunology

• Publication date

  2011-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1100016PMID 21715687PMCID PMC3152989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.

  2010cited by this paper
• Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

  2010cited by this paper
• CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden

  2009cited by this paper
• A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM).

  2009cited by this paper
• Dendritic Cells and Monocyte/Macrophages That Create the IL-6/APRIL-Rich Lymph Node Microenvironments Where Plasmablasts Mature1

  2009cited by this paper
• Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

  2009cited by this paper
• Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

  2009cited by this paper
• Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells.

  2009influential reference
• Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma.

  2009cited by this paper
• Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

  2008cited by this paper
• Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.

  2008cited by this paper
• Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.

  2008cited by this paper
• CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation

  2008cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007influential reference
• Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

  2007cited by this paper
• Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma

  2007cited by this paper
• On watching the watchers: IDO and type I/II IFN

  2007cited by this paper
• Tryptophan catabolism in IDO+ plasmacytoid dendritic cells.

  2007cited by this paper
• Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells.

  2006cited by this paper
• Enhancement of clonogenicity of human multiple myeloma by dendritic cells

  2006cited by this paper
• In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

  2006cited by this paper
• Regulation of RelB Expression during the Initiation of Dendritic Cell Differentiation

  2005cited by this paper
• Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma

  2005cited by this paper
• Protein Kinase C βII Plays an Essential Role in Dendritic Cell Differentiation and Autoregulates Its Own Expression*

  2005cited by this paper
• CD28-mediated regulation of multiple myeloma cell proliferation and survival.

  2005cited by this paper
• GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

  2005cited by this paper
• Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.

  2004cited by this paper
• CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86

  2004cited by this paper
• Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells1

  2004influential reference
• Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells.

  2004cited by this paper
• Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

  2004cited by this paper
• Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.

  2004cited by this paper
• Plasmacytoid dendritic cells in immunity

  2004cited by this paper
• Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6.

  2003cited by this paper
• The CD28 signaling pathway regulates glucose metabolism.

  2002cited by this paper
• T cell apoptosis by tryptophan catabolism

  2002cited by this paper
• CTLA-4–Ig regulates tryptophan catabolism in vivo

  2002influential reference
• Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells.

  2002influential reference
• T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells

  2002cited by this paper
• Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+ dendritic cells

  2002cited by this paper
• Generation of Human CD8 T Regulatory Cells by CD40 Ligand–activated Plasmacytoid Dendritic Cells

  2002cited by this paper
• The Role of Bone Marrow-Derived Stromal Cells in the Maintenance of Plasma Cell Longevity1

  2002cited by this paper
• Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression.

  2001cited by this paper
• B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy.

  2000cited by this paper
• Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.

  2000cited by this paper
• Cell–cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity

  2000cited by this paper
• High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma

  1999cited by this paper
• Dendritic Cells Enhance the Differentiation of Naïve B Cells into Plasma Cells In Vitro

  1998cited by this paper
• CD28, a marker associated with tumoral expansion in multiple myeloma.

  1998cited by this paper
• Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients.

  1997cited by this paper
• IL-6 rescues resting mouse T cells from apoptosis.

  1997cited by this paper
• CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL.

  1995cited by this paper
• Interleukin-6 inhibits apoptosis of malignant plasma cells.

  1995cited by this paper
• The B7 and CD28 receptor families.

  1994cited by this paper
• A new, simple, bioassay for human IFN-gamma.

  1994cited by this paper
• A new, simple, bioassay for human IFN-γ

  1994cited by this paper
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993influential reference
• Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

  1989cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells.

  1987cited by this paper
• EXCRETION OF TRYPTOPHAN METABOLITES IN DIFFERENT FORMS OF HAEMOBLASTOSIS.

  1964cited by this paper

• Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era

  2025cites this paper
• RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.

  2025cites this paper
• Pro-survival signaling regulates lipophagy essential for multiple myeloma resistance to stress-induced death

  2024influential citation
• Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma

  2024cites this paper
• Exploring cellular immunotherapy platforms in multiple myeloma

  2024cites this paper
• Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice.

  2023cites this paper
• Therapeutic strategies to enhance immune response induced by multiple myeloma cells

  2023cites this paper
• Crosstalk in the diseased plasma cell niche – the force of inflammation

  2023cites this paper
• Serum soluble CD86 levels correlate with CD86 variant 3 gene expression and are prognostic indicators in myeloma.

  2023cites this paper
• Addition of interleukin‐6 receptor blockade to carfilzomib‐based desensitization in a highly sensitized nonhuman primate model

  2022cites this paper
• PDZ proteins SCRIB and DLG1 regulate myeloma cell surface CD86 expression, growth, and survival.

  2022cites this paper
• Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma

  2022cites this paper
• Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry

  2021cites this paper
• Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression

  2021influential citation
• Role and Modulation of NK Cells in Multiple Myeloma

  2021cites this paper
• Game of Bones: How Myeloma Manipulates Its Microenvironment

  2021cites this paper
• Indoleamine 2,3-dioxygenase 1 is essential for sustaining durable antibody responses.

  2021cites this paper
• Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma

  2021cites this paper
• B-cell biology, tolerance, and autoantibodies

  2021cites this paper
• Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy

  2021cites this paper
• The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma

  2021cites this paper
• Immunotherapeutic Strategies for Multiple Myeloma

  2020cites this paper
• Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches

  2020cites this paper
• CD28 is expressed by macrophages with anti‐inflammatory potential and limits their T‐cell activating capacity

  2020cites this paper
• IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment.

  2020cites this paper
• Experimental modeling of desensitization: What have we learned about preventing AMR?

  2020cites this paper
• Unraveling the mysteries of plasma cells.

  2020cites this paper
• Cellular Immunotherapy for Multiple Myeloma

  2019cites this paper
• Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

  2019cites this paper
• Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

  2019cites this paper
• Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation.

  2019cites this paper
• Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation.

  2019cites this paper
• Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Time for an Obituary or Not Just Yet!

  2019cites this paper
• Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle

  2019cites this paper
• The Maintenance of Memory Plasma Cells

  2019cites this paper
• Diversity of CD28null T Cells in the Elderly: A Glimpse in a Biological Adaptation of Aging

  2019cites this paper
• Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.

  2019cites this paper
• CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction

  2018cites this paper
• Pre-existing malignancy results in increased prevalence of distinct populations of CD4+ T cells during sepsis

  2018cites this paper
• Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients

  2018cites this paper
• Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma

  2018cites this paper
• Plasma cells: The programming of an antibody‐secreting machine

  2018cites this paper
• Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

  2017cites this paper
• The effect of CTLA-4 and CD28 gene variants and circulating protein levels in patients with gastric cancer

  2017cites this paper
• Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

  2017cites this paper
• Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness.

  2017cites this paper
• The multi-faceted potential of CD38 antibody targeting in multiple myeloma

  2017cites this paper
• CD86 regulates myeloma cell survival.

  2017cites this paper
• Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs

  2017cites this paper
• Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.

  2016cites this paper
• Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma

  2016cites this paper
• Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1

  2016cites this paper
• Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma

  2016cites this paper
• Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma

  2016cites this paper
• CD 28 expressing B cells and ACPA + plasmablasts /-cells of Rheumatoid arthritis patients Chapter 5

  2016cites this paper
• Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.

  2016cites this paper
• Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

  2015cites this paper
• Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

  2015cites this paper
• Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.

  2015cites this paper
• LYMPHOID NEOPLASIA Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8 1 T-cell killing

  2015cites this paper
• CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif

  2015cites this paper
• Characterization of a new human plasma cell leukemia cell line UHKT‐944

  2015cites this paper
• Cereblon binding molecules in multiple myeloma.

  2015cites this paper
• A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow.

  2015cites this paper
• A Systemic Review of Clinical Trials on Dendritic-Cells Based VaccineAgainst Malignant Glioma

  2015cites this paper
• Multiple Myeloma and Evolution of Novel Biomarkers and Therapies

  2014cites this paper
• Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation

  2014cites this paper
• Novel Regulation of CD80/CD86-induced Phosphatidylinositol 3-Kinase Signaling by NOTCH1 Protein in Interleukin-6 and Indoleamine 2,3-Dioxygenase Production by Dendritic Cells*♦

  2014cites this paper
• Tumor-Induced STAT3 Signaling in Myeloid Cells Impairs Dendritic Cell Generation by Decreasing PKCβII Abundance

  2014cites this paper
• CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.

  2014cites this paper
• Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

  2014cites this paper
• Cellular immunotherapy in multiple myeloma: lessons from preclinical models.

  2014cites this paper
• Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM).

  2013cites this paper
• Mechanisms of allergic diseases

  2013cites this paper
• Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.

  2013cites this paper
• Post-interventional atherosclerotic vascular remodeling : preclinical investigation into immune-modulatory therapies

  2013cites this paper
• The CD28/B7 pathway: a novel regulator of plasma cell function.

  2013cites this paper
• Immune dysfunction in multiple myeloma

  2013cites this paper
• B-cell biology and development.

  2013cites this paper
• CD28–B7 Interaction Modulates Short- and Long-Lived Plasma Cell Function

  2012cites this paper
• Heterogeneity of the bone marrow plasma cell pool (109.14)

  2012cites this paper
• Under one roof

  2012influential citation
• EPHA3 as a novel therapeutic target in the hematological malignancies

  2012cites this paper
• Immunophenotyping by Flow Cytometry in Multiple Myeloma: Advantages for Diagnosis and Minimal Residual Disease Monitoring

  2012cites this paper
• 2012 Landes Bioscience. Do not distribute. Under one roof The bone marrow survival niche for multiple myeloma and normal plasma cells

  2012cites this paper
• Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes

  2012cites this paper
• Indoleamine 2,3-Dioxygenase and Dendritic Cell Tolerogenicity

  2012influential citation
• Pathogenic Long-Lived Plasma Cells and Their Survival Niches in Autoimmunity, Malignancy, and Allergy

  2012cites this paper
• Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma

  2012influential citation
• Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.

  2012cites this paper
• Staying alive: regulation of plasma cell survival.

  2011cites this paper
• Malignancy, and Allergy Their Survival Niches in Autoimmunity, Pathogenic Long-lived Plasma Cells And

  year unknowncites this paper